<DOC>
	<DOCNO>NCT02497898</DOCNO>
	<brief_summary>The purpose study study safety efficacy chemotherapy usage follow CIK transfusion refractory and/or chemoresistant lymphoma .</brief_summary>
	<brief_title>Treatment CIK Patients With Refractory Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>Autologous cytokine-induced killer ( CIK ) cell transfusion ( &gt; 2*10^9 cell count ) within 2 week regular chemotherapy every 3 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>diagnose nonHodgkin lymphoma negative effect regular chemotherapy , need therapy patient refuse therapy tolerance therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>